RDY vs. KRTX, UTHR, SRPT, BGNE, VTRS, CTLT, TEVA, ROIV, LEGN, and ASND
Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Karuna Therapeutics (KRTX), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), BeiGene (BGNE), Viatris (VTRS), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Roivant Sciences (ROIV), Legend Biotech (LEGN), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.
Dr. Reddy's Laboratories (NYSE:RDY) and Karuna Therapeutics (NASDAQ:KRTX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
Dr. Reddy's Laboratories currently has a consensus target price of $80.00, suggesting a potential upside of 8.89%. Karuna Therapeutics has a consensus target price of $293.92, suggesting a potential downside of 10.89%. Given Dr. Reddy's Laboratories' higher possible upside, research analysts clearly believe Dr. Reddy's Laboratories is more favorable than Karuna Therapeutics.
In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Karuna Therapeutics. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 3 mentions for Karuna Therapeutics. Karuna Therapeutics' average media sentiment score of 0.23 beat Dr. Reddy's Laboratories' score of 0.17 indicating that Karuna Therapeutics is being referred to more favorably in the news media.
Dr. Reddy's Laboratories has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
Dr. Reddy's Laboratories received 196 more outperform votes than Karuna Therapeutics when rated by MarketBeat users. However, 66.29% of users gave Karuna Therapeutics an outperform vote while only 59.02% of users gave Dr. Reddy's Laboratories an outperform vote.
Dr. Reddy's Laboratories has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
Dr. Reddy's Laboratories has a net margin of 19.26% compared to Karuna Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 20.97% beat Karuna Therapeutics' return on equity.
14.0% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 13.2% of Karuna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Dr. Reddy's Laboratories beats Karuna Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Dr. Reddy's Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Reddy's Laboratories Competitors List
Related Companies and Tools
